Prophylactic human vaccines stimulate the immune response and are intended for ameliorating the effects of future infection caused by pathogens in human beings. Novel vaccine development technologies such as viral-like particles are used in developing Hepatitis B Virus (HBV) vaccines, and Human Papilloma Virus (HPV) vaccines. For instance, in March 2014, CureVac AG received EUR 2 million Vaccine Prize from European Commission for its novel RNActive vaccine technology. This RNActive vaccine technology enables production of safe, efficacious, and cost-effective vaccines that are protected against elevated temperature as well as inadvertent freezing.
Prophylactic Human Vaccine Market – Drivers
Increasing number of pipeline studies and rising involvement of key players for vaccine development is expected to propel growth of the prophylactic human vaccine market during the forecast period. For instance, in October 2018, CureVac AG, announced to initiate dose escalation phase I clinical trial for CV7202 mRNA-based rabies vaccine. CV7202 is a prophylactic vaccine encoding RABV-G, the rabies virus glycoprotein. This will enable vaccinated individual's own cells to produce RABV-G protein, by which immune response gets triggered. This study is estimated to complete in January 2021.
Moreover, in October 2018, Valneva SE announced progress in its Phase 1 program targeting a single-shot vaccine against Chikungunya. It is designed for prophylactic, active, single-dose immunization against Chikungunya in humans. The vaccine aims for long-lasting protection and an anticipated safety profile similar to other approved vaccines for active immunization in adults and children.
Furthermore, rising initiatives by various scientists to develop innovative solutions to fight against infectious diseases is expected to drive growth of the market. For instance, VBI Vaccines Inc., in September 2018, announced formation of three Scientific and Clinical Advisory Boards (SABs) comprising leading experts in infectious disease and immuno-oncology research and vaccine development targeting hepatitis B, Cytomegalovirus (CMV), and Glioblastoma (GBM). This collaboration is expected to propel growth of the market, owing to enhanced vaccine development.
Prophylactic Human Vaccine Market – Restraint
Significant barriers in the vaccine development such as virus diversity and limited number of animal models are estimated to hamper growth of the prophylactic human vaccine market. For instance, according to Gastroenterology, in October 2018, vaccine development requires huge investment from various resources and is very challenging. Designing vaccine trials in human is difficult since following immunization the chances for develop an acute infection is very high. Therefore, anti-viral treatment has to be offered immediately, which makes it a challenging task to manage disease.
Prophylactic Human Vaccine Market – Regional Analysis
On the basis of region, the global prophylactic human vaccine market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.
Geographically, North America is probable to lead in the global prophylactic human vaccine market, owing to receiving large number of research grants by government. For instance, in September 2018, GeoVax Labs, Inc., U.S.-based company recieved grant of US$ 2,442,307 by the U.S. Army Medical Research Acquisition Activity. The grant was awarded as a cooperative agreement for novel Lassa Fever (LF) vaccine (GEO-LM01) development program. GEO-LM01 uses Modified Vaccinia Ankara (MVA) and Virus-Like Particle (VLP) vaccine platform that has been demonstrated to be safe and induce antibody responses in patients. Moreover, MVA-VLP platform has shown effective results in other cases such as GeoVax’s prophylactic HIV vaccine, GeoVax’s Ebola (EBOV) vaccine, and GeoVax’s Zika vaccine in its respective preclinical studies.
Europe region is also expected to perceive extensive growth in prophylactic human vaccine market, due to rising initiatives by government for developing efficient and safe vaccines. For instance, in October 2017, the European Commission funded TRANSVAC, a new infrastructure project. This project aims to rapidly develop effective vaccines in order to address European health challenges and in turn increase the sustainability of EC vaccine projects in Europe. TRANSVAC offers high-quality technical services to support development of prophylactic and therapeutic vaccines for both human and animal use.
The key players operating in prophylactic human vaccine market include, GlaxoSmithKline Plc., Merck & Co., Inc., Pfizer Inc., Janssen Pharmaceuticals, Inc., Altimmune, Inc., Bharat Biotech International Limited, Serum Institute of India Pvt. Ltd., Sanofi Pasteur SA, Shanghai BravoBio Co., Ltd., SK Chemicals Co., Ltd., Takeda Pharmaceutical Company Limited, BiondVax Pharmaceuticals Ltd., and SK Chemicals Co., Ltd.
Prophylactic Human Vaccine Market – Taxonomy
By Vaccine Technology
Coherent Market Insights followsa comprehensive research methodology focused on providing the most precise market analysis. The company leverages a data triangulation model which helps company to gauge the market dynamics and provide accurate estimates. Key components of the research methodologies followed for all our market reports include:
In addition to this, Coherent Market Insights has access to a wide range of the regional and global reputed paid data bases, which helps the company to figure out the regional and global market trends and dynamics. The company analyses the industry from the 360 Degree Perspective i.e. from the Supply Side and Demand Side which enables us to provide granular details of the entire ecosystem for each study. Finally, a Top-Down approach and Bottom-Up approach is followed to arrive at ultimate research findings.
Coherent Market Insights desk research is based on a principle set of research techniques:
Coherent Market Insights has a large amount of in-house repository of industry database. This is leveraged as a burner for initiating a new research study. Key secondary sources include:
Preliminary Data Mining
The raw data is obtained through the secondary findings, in house repositories, and trade surveys. It is then filtered to ensure that the relevant information including industry dynamics, trends, and outlook is retained for further research process.
Holistic approach is used to ensure that the granular and uncommon parameters are taken into consideration to ensure accurate results. The information from the paid databases are further combined to the raw data in order to standardize it.
Coherent Statistical model
We arrive at our final research findings through simulation models. Coherent Data Analytics Model is a statistical tool that helps company to forecast market estimates. Few of the parameters considered as a part of the statistical model include:
Once the findings are derived from the statistical model, large volume of data is process to confirm accurate research results. Data analytics and processing tools are adopted to process large chunk of collected informative data. In case, a client customizes the study during the process, the research finding till then are benchmarked, and the process for new research requirement is initiated again.
This is the most crucial stage of the research process. Primary Interviews are conducted to validate the data and analysis. This helps in achieving the following purposes:
The primary research is conducted with the ecosystem players including, but not limited to:
Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.[email protected]
Talk to our research consultant to design an exclusive report as per your research needs.
We aim to fulfil client's research demands with tailored research solutions.
We aim to provide research studies in quickest turnaround time and in a much cost effective manner.
We cover each industry from supply and demand side with an aim to provide a most holistic research study.
We strive to provide most accurate and reliable research findings in our research reports.